CLINICAL TRIALS PROFILE FOR PREMARIN

505(b)(2) Clinical Trials for PREMARIN

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Formulation	NCT00380887 ↗	Study Comparing Four New Formulations for Premarin in Healthy Postmenopausal Women	Completed	Wyeth is now a wholly owned subsidiary of Pfizer		2005-06-01	The purpose of this study is to determine bioequivalence and bioavailability of four different Premarin/MPA test formulations versus the current formulation for Prempro.
New Formulation	NCT00381251 ↗	Study Comparing Bioequivalence of Two New Formulations of Premarin/MPA With Premarin/MPA Reference Formulation.	Completed	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 1	2006-09-01	This study will compare the bioequivalence of two new investigational combination formulations of Premarin and medroxyprogesterone acetate (MPA) with a currently marketed formulation of Premarin and medroxyprogesterone, Prempro™. Prempro is indicated for use after menopause in women with a uterus to reduce moderate to severe hot flashes; to treat moderate to severe dryness, itching, and burning, in and around the vagina; and to help reduce your chances of getting osteoporosis (thin weak bones). The purpose of this study is to determine if these new formulations of Premarin and MPA provide the same levels of estrogen and MPA in the blood as Prempro in healthy postmenopausal women.
New Formulation	NCT00401219 ↗	Study Comparing Bioavailability of 3 New Formulations of Premarin/MPA With Premarin/MPA (PREMPRO) Reference Formulation	Completed	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 1	2006-11-01	This study will compare the bioavailabity of three new investigational combination formulations of Premarin and medroxyprogesterone acetate (MPA) with a currently marketed formulation of Premarin and MPA, Prempro™. Prempro™ is indicated for use after menopause in women with a uterus to reduce moderate to severe hot flashes; to treat moderate to severe dryness, itching, and burning, in and around the vagina; and to help reduce your chances of getting osteoporosis (thin weak bones). The purpose of this study is to determine if these new formulations of Premarin/MPA provide the same levels of estrogen and MPA in the blood as Prempro in healthy postmenopausal women.
New Formulation	NCT00472927 ↗	Bioequivalence Study of 3 New Formulations of Premarin/MPA Compared With Premarin/MPA (Prempro)	Completed	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 1	2007-05-01	To evaluate three new investigational tablet formulations of the Food and Drug Administration (FDA) approved medication Prempro™, Premarin combined with medroxyprogesterone acetate (MPA).
New Formulation	NCT00630435 ↗	Study Comparing 3 New Formulations of Premarin® 0.625 mg/MPA 2.5 mg With a Reference Formulation	Completed	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 1	2008-02-01	The purpose of this trial is to determine the equivalence of 3 new formulations of a Premarin®/medroxyprogesterone acetate (MPA) combination tablet to the currently marketed dosage form (Prempro® [TM]). This study will be performed in healthy postmenopausal women. Each subject will participate in the study for approximately 14 weeks, including a screening evaluation within 3 weeks before the study, and four, 6-day, 5-night inpatient periods with at least a 21-day washout interval between each dose administration.

All Clinical Trials for PREMARIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000175 ↗	The Effects of Sex Hormones on Cognition and Mood in Older Adults	Terminated	National Institute on Aging (NIA)	N/A	1969-12-31	This study is investigating the effects of hormone replacement therapy on memory, mental abilities and mood in older adults aged 65-90. During the nine month long study, men will take testosterone for three months and women will take estrogen for three months. At four points during the study (once every three months), participants will complete a test battery and have blood drawn.
NCT00000555 ↗	Women's Angiographic Vitamin and Estrogen Trial (WAVE)	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1996-08-01	To assess whether hormonal replacement therapy and/or antioxidant treatment would stabilize or inhibit progression, and induce regression of coronary plaques. The mechanisms by which these treatments modified atherosclerosis in women were also explored.
NCT00002976 ↗	Estrogen Replacement Therapy in Treating Women With Early-Stage Endometrial Cancer	Terminated	Eastern Cooperative Oncology Group	Phase 3	1997-06-01	RATIONALE: Estrogen replacement therapy may improve quality-of-life in postmenopausal women with endometrial cancer. It is not yet known whether estrogen replacement therapy will affect cancer recurrence. PURPOSE: Randomized double-blinded phase III trial to determine the effectiveness of estrogen replacement therapy in treating women who have stage I or stage II endometrial cancer.
NCT00002976 ↗	Estrogen Replacement Therapy in Treating Women With Early-Stage Endometrial Cancer	Terminated	National Cancer Institute (NCI)	Phase 3	1997-06-01	RATIONALE: Estrogen replacement therapy may improve quality-of-life in postmenopausal women with endometrial cancer. It is not yet known whether estrogen replacement therapy will affect cancer recurrence. PURPOSE: Randomized double-blinded phase III trial to determine the effectiveness of estrogen replacement therapy in treating women who have stage I or stage II endometrial cancer.
NCT00002976 ↗	Estrogen Replacement Therapy in Treating Women With Early-Stage Endometrial Cancer	Terminated	Southwest Oncology Group	Phase 3	1997-06-01	RATIONALE: Estrogen replacement therapy may improve quality-of-life in postmenopausal women with endometrial cancer. It is not yet known whether estrogen replacement therapy will affect cancer recurrence. PURPOSE: Randomized double-blinded phase III trial to determine the effectiveness of estrogen replacement therapy in treating women who have stage I or stage II endometrial cancer.

Clinical Trial Conditions for PREMARIN

Condition Name

Condition Name for PREMARIN
Intervention	Trials
Postmenopause	10
Menopause	8
Pelvic Organ Prolapse	3
Atrophic Vaginitis	2

Condition MeSH

Condition MeSH for PREMARIN
Intervention	Trials
Vaginitis	4
Prolapse	4
Pelvic Organ Prolapse	4
Hot Flashes	3

Clinical Trial Locations for PREMARIN

Trials by Country

Trials by Country for PREMARIN
Location	Trials
United States	150
Germany	7
Canada	6
United Kingdom	5
Australia	3

Trials by US State

Trials by US State for PREMARIN
Location	Trials
Florida	9
Texas	8
Massachusetts	7
California	7
Arizona	6

Clinical Trial Progress for PREMARIN

Clinical Trial Phase

Clinical Trial Phase for PREMARIN
Clinical Trial Phase	Trials
Phase 4	10
Phase 3	6
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for PREMARIN
Clinical Trial Phase	Trials
Completed	38
Terminated	5
Recruiting	3

Clinical Trial Sponsors for PREMARIN

Sponsor Name

Sponsor Name for PREMARIN
Sponsor	Trials
Wyeth is now a wholly owned subsidiary of Pfizer	13
Brigham and Women's Hospital	4
University of Washington	4

Sponsor Type

Sponsor Type for PREMARIN
Sponsor	Trials
Other	69
Industry	23
NIH	8

Clinical Trials Update, Market Analysis, and Forecast for Premarin (Conjugated Estrogens)

Last updated: January 27, 2026

Executive Summary

Premarin, the brand name for conjugated estrogens primarily derived from mare urine, has maintained a significant presence in hormone replacement therapy (HRT) for menopausal women for over 80 years. Despite declining usage due to safety concerns and the advent of newer therapies, Premarin remains widely prescribed. This report synthesizes the latest clinical trial developments, conducts a market landscape analysis, and projects future trends up to 2030. The insights assist pharmaceutical stakeholders in strategic decision-making, considering regulatory shifts, competitive dynamics, and evolving clinical evidence.

---

Clinical Trials Update on Premarin

Current Clinical Research Status

As of Q1 2023, there are limited ongoing clinical trials specifically targeting Premarin. Most recent research focuses on hormone replacement therapy (HRT) safety, alternative formulations, and comparative effectiveness rather than new efficacy data for Premarin itself.

Trial ID	Title	Status	Focus	Enrollment	Sponsored By	Expected Completion
NCT04985812	Comparing Estrogen Therapies in Menopause	Recruiting	HRT efficacy, safety	4,500	NIH	Dec 2024
NCT04568761	Estrogen and Cardiovascular Risk	Completed	Cardiovascular impacts	3,200	Various academic centers	Jan 2022
NCT03108376	Topical versus Oral Estrogen	Active, not recruiting	Delivery methods	1,000	Industry	Dec 2023

Key Findings from Recent Studies

• Safety Profile: Recent meta-analyses (e.g., Soh et al., 2022) confirm increased risks of venous thromboembolism (VTE), stroke, and certain cancers with systemic estrogen therapy, including Premarin.
• Efficacy: Consistent relief of menopausal symptoms—vasomotor instability and vaginal dryness—remains the primary benefit.
• New Formulations: Investigations into transdermal patches and gels aim to mitigate systemic risks but are not yet titrated for distinct superiority over oral Premarin.

Regulatory Updates

• The FDA continues to classify Premarin as a Prescription Drug with REMS (Risk Evaluation and Mitigation Strategies) due to safety concerns, emphasizing informed patient consent.
• Updates on labeling are under review to incorporate recent findings on cardiovascular and cancer risks.

---

Market Landscape Analysis

Global Market Size and Historical Trends

Region	2018 (USD millions)	2022 (USD millions)	CAGR (%) (2018-2022)	Remarks
North America	530	620	4.0	Dominant due to aging population and high HRT usage
Europe	410	440	2.7	Market contraction seen from 2018 onwards
Asia-Pacific	150	220	14.3	Emerging market amid rising awareness
Rest of World	90	100	2.5	Limited penetration

Total Global Market (2018): USD 1.18 billion
Total Global Market (2022): USD 1.38 billion

Key Market Drivers

• Increasing menopausal population globally (WHO estimates ~1.25 billion women aged 50+ by 2030)
• Prescribed for osteoporosis prevention in aging women
• Long-standing physician familiarity and brand loyalty for Premarin

Market Segmentation

Segment	Share (2022)	Key Characteristics	Trends
Oral Premarin	65%	Most prescribed form	Growing concerns over oral safety profile
Topical Estrogens (Creams/Gels)	20%	Reduced systemic risk	Increasing adoption for localized therapy
Injectable/Other Forms	15%	Limited use historically	Potential future niche growth

Competitive Landscape

Competitor	Drug/Product	Market Share	Differentiators	Notes
Wyeth/Pfizer	Premarin	~80%	Established brand, extensive clinical data	Facing decreasing prescriptions
Novo Nordisk	Menopur (for fertility, not HRT)	N/A	Focused elsewhere	Limited competition in HRT
Innovative biotech firms	New bioidentical estrogens	N/A	Safer profiles	Growing interest, regulatory hurdles

Regulatory Environment and Policy Impact

• EMA and FDA**: Reiterate strict prescribing guidelines and risk disclosures
• Insurance Reimbursements: Limited coverage for HRT options with safer profiles, impacting consumption patterns
• Patent and Exclusivity: Patents for Premarin formulations expired, leading to biosimilar competition outside the US

---

Market Projection: 2023–2030

Forecast Assumptions

• Slight annual decline in oral Premarin usage (~1.5–2%) due to safety concerns and market saturation
• Uptake of transdermal and topical formulations is expected to grow at CAGR of 8–10%
• Emerging interest in bioidentical hormone therapies which may cannibalize Premarin’s market share
• Regulatory pressures may further restrict prescribing of systemic estrogens

Projected Market Size (USD Millions)

Year	Total Market (USD millions)	Premarin Share	Projected Premarin Market	Notes
2023	1.40	80%	1,120	Baseline year
2025	1.52	70%	1,064	Decline persists
2027	1.65	60%	990	Shift toward alternative therapies
2030	1.80	50%	900	Market stabilization at lower levels

Key Market Factors

• Aging Demographics: Sustains a steady demand for HRT
• Safety concerns: May accelerate decline in systemic estrogen prescriptions
• New Formulations: Potential for growth if safety profiles improve
• Regulatory actions: Could impose restrictions or require updated labeling, affecting sales

---

Comparison to Alternative Estrogen Therapies

Therapy	Formulation	Safety Profile	Key Advantages	Market Share (2022)
Premarin	Conjugated estrogens	VTE, cancer risks	Long history, familiarity	80% in HRT segment
Bioidentical Estrogens	Estradiol, Estrone	Lower VTE risk	Customizable, perceived safer	15% – 20% growth
Synthetic Estrogens	Ethinylestradiol	Higher systemic risks	Oral bioavailability	Declining use in HRT

---

Deep Dive: Future Opportunities and Risks

Opportunities

• Development of safer formulations: Transdermal patches or gels with favorable safety profiles.
• Biosimilars and generics: Expanded options may reduce costs and increase accessibility.
• Personalized medicine: Tailoring hormone therapy based on genomic and biomarker data.

Risks

• Regulatory tightening: Stricter guidelines could limit indications and prescriptions.
• Market backlash: Heightened public awareness of safety issues may decrease demand.
• Competing therapies: Rise of plant-based or bioidentical alternatives.

---

Key Takeaways

• Premarin remains a major player in HRT but faces sharp declines driven by safety concerns and alternative therapies.
• Clinical trials continue to focus on improving safety profiles and exploring delivery methods.
• The global market is expected to shrink modestly in systemic formulations; however, topical alternatives may offset some declines.
• Regulatory pressures and evolving clinical evidence will shape Preserving or diminishing its market dominance.
• Strategic positioning around developing safer formulations and educating providers is essential for stakeholders.

---

FAQs

1. What are the latest safety concerns associated with Premarin?
Systemic estrogen therapy, including Premarin, is linked to increased risks of venous thromboembolism, stroke, breast, and endometrial cancers, prompting regulatory agencies to implement stricter prescribing guidelines.

2. Is Premarin still recommended for menopausal women?
Yes, but with caution. It is typically prescribed for women with severe menopausal symptoms who are counseled on risks, and alternative therapies are increasingly preferred.

3. How does the market for Premarin compare to bioidentical hormones?
Bioidentical hormones have gained popularity due to perceived safety benefits, capturing a growing share, especially among younger menopausal women seeking personalized treatment.

4. Are there recent regulatory changes affecting Premarin availability?
The FDA maintains strict guidelines, emphasizing informed consent and risk disclosures. No recent bans but continued monitoring influences prescribing practices.

5. What new developments could impact Premarin's future?
Innovations in safer delivery systems, bioidentical formulations, and biosimilars could further erode Premarin's market share, especially if they demonstrate improved safety profiles.

---

References

1. Soh, J., et al. (2022). Meta-analyses on estrogen therapy safety. The Journal of Menopause.
2. FDA. (2022). Use of Hormone Therapy: Risks and Benefits. Guideline Document.
3. World Health Organization. (2021). Menopause and Aging Population Data.
4. MarketResearch.com. (2023). Global Estrogen Replacement Market Report.
5. European Medicines Agency. (2022). Hormone Replacement Therapy position paper.